Actin-tTS Tg, B6-ACTB-tTS Tg Actin-tTS Tg, B6-ACTB-tTS Tg Carrier x Noncarrier [C57BL/6JJcl] <a href='https://brc.riken.jp/mus/pcr05447'>Genotyping protocol -PCR-</a> true 条件を付加する。<br>The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for publication of research papers. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature designated by the DEVELOPER (Dr. Moises Mallo, (Max-Plank Institute of Immunobiology) is requested.　Ｇｅｎｏｍｉｃｓ，　81（4）：356-360 2003. The RECIPIENT must　contact　the DEVELOPER in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. 　　For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEVELOPER and must obtain a prior written consent from the DEVELOPER. Tet system 田中　謙二 Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> C（3〜6か月） 田中先生が開発者Dr. Moises Malloより2008年に生理研へ導入。系統の由来 : 不明 Kenji TANAKA 全身の細胞でtTSを発現する。tetOをノックインしたホモ接合体との組み合わせで遺伝子ノックダウンが可能になる。 入手後129S6へ10代バッククロスしてある。 田中先生が開発者Dr. Moises Malloより2008年に生理研へ導入。 系統の由来 : 不明 B6.Cg-Tg(ACTB-tTS)1Mllo B6.Cg-Tg(ACTB-tTS)1Mllo human beta actin promoter, tTS (E. coli Tetracycline repressor (tetR), human ZFP KRAB domain cDNA), chicken globin genomic DNA, SV40 polyA signal C (3-6 months) RBRC05447 The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for publication of research papers. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature designated by the DEVELOPER (Dr. Moises Mallo, (Max-Plank Institute of Immunobiology) is requested. Genomics, 81(4):356-360 2003. The RECIPIENT must contact the DEVELOPER in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEVELOPER and must obtain a prior written consent from the DEVELOPER. ACTB-tTS transgenic mice. These mice express tetracycline-controlled transcriptional silencer (tTS) gene under the control of the human beta actin promoter. By the combination with homozygous tetO-modified allele, expression from the gene can be blocked in the absence of doxycycline and restore when the antibiotic is administered to the animal. Developed by Moises Mallo, Max-Plank Institute of Immunobiology. C57BL/6 and 129 mixed background.